Conditions: Cutaneous T-Cell Lymphoma Peripheral T-Cell Lymphoma Non-Hodgkin's Lymphoma
Keywords: CTCL PTCL lymphoma Non-Hodgkin's Lymphoma Cutaneous T-Cell Lymphomas (CTCL) Peripheral T-Cell Lymphomas (PTCL) Other Types of Non-Hodgkin's Lymphoma belinostat
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 53
Healthy volunteers: no

Brief summary:
Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Patients are treated with belinostat(PXD101) 1000 mg/m2 on days 1-5 of a 21 day cycle.

Detailed description:

Arms:
arm 1: PXD101 1000 mg/m2 once daily for 5 days every 21 days arm 2: PXD101 1000 mg/m2 once daily for 5 days every 21 days

Interventions: intervention 1: belinostat
Intervention descriptions: intervention 1: None

Protocol document: